Role of galectin-3 and CD44v6 expression in the differentiation of the follicular carcinoma and adenoma of the thyroid -

Objective: The role of the galectin-3 and CD44v6 expression in the differentiation of the thyroid follicular carcinoma and follicular adenoma were investigated in many preoperative cytologic samples and significant results were achieved. In this study, we investigated galectin-3 and CD44v6 as potential supportive markers of histopathologic diagnosis in the differentiation of follicular carcinoma and adenoma of thyroid in conventional tissue sections. Material and Method: A total of 60 thyroidectomy specimens from Kartal Dr. LA¼tfi KA½rdar Training and Research Hospital and Istanbul University Cerrahpasa Medical Faculty Pathology Department were investigated retrospectively. Twenty cases of the 60 thyroidectomy specimens were diagnosed as follicular carcinoma and 40 cases were diagnosed as follicular adenoma. Sections taken adjacent to the capsule of the nodule were stained immunohistochemically by HRP-AEC method for galectin-3 and CD44v6 antibody. Then sections were investigated under light microscope and labeled as no staining (-), focal weak staining (+), moderately intense staining (++), intense staining (+++). Results: Galectin-3 expression was significant in the differentiation of the follicular carcinoma and adenoma (p0.05). Conclusion: Galectin-3 was determined as a potential marker in the diagnosis of follicular carcinoma but CD44v6 expression was not a diagnostic value in the differentiation of follicular carcinoma and adenoma.

[1]  A. Shivarudrappa,et al.  Galectin-3 Immunohistochemical Expression in Thyroid Neoplasms. , 2015, Journal of clinical and diagnostic research : JCDR.

[2]  I. Soldatovic,et al.  Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature , 2015, Diagnostic Pathology.

[3]  T. Krausz,et al.  A Pilot Study of Galectin-3, HBME-1, and p27 Triple Immunostaining Pattern for Diagnosis of Indeterminate Thyroid Nodules in Cytology With Correlation to Histology , 2015, Applied immunohistochemistry & molecular morphology : AIMM.

[4]  Taiseer R. Ibrahim,et al.  Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules. , 2014, Pathology, research and practice.

[5]  D. Das,et al.  Contribution of immunocytochemical stainings for galectin‐3, CD44, and HBME1 to fine‐needle aspiration cytology diagnosis of papillary thyroid carcinoma , 2014, Diagnostic cytopathology.

[6]  S. Barollo,et al.  Galectin‐3 expression in thyroid fine needle cytology (t‐FNAC) uncertain cases: Validation of molecular markers and technology innovation , 2013, Journal of cellular physiology.

[7]  N. Siddaraju,et al.  Role of pro-angiogenic marker galectin-3 in follicular neoplasms of thyroid. , 2012, Indian Journal of Biochemistry & Biophysics.

[8]  Z. Kusic,et al.  Intensity and distribution of immunohistochemical expression of galectin-3 in thyroid neoplasms. , 2012, Acta clinica Croatica.

[9]  M. Beesley,et al.  Cytokeratin 19 and galectin‐3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules , 2002, Histopathology.

[10]  K. Nabeshima,et al.  Diagnostic utility of galectin‐3 and CD26/DPPIV as preoperative diagnostic markers for thyroid nodules , 2002, Diagnostic cytopathology.

[11]  F. Negro,et al.  Galectin‐3, a marker of well‐differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia , 2002, Histopathology.

[12]  P. De Giuli,et al.  Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. , 2001, The Journal of clinical endocrinology and metabolism.

[13]  A. Vecchione,et al.  Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions , 2001, The Lancet.

[14]  C. Cheung,et al.  Immunohistochemical Diagnosis of Papillary Thyroid Carcinoma , 2001, Modern Pathology.

[15]  S. Savin,et al.  Galectin‐3 and carcinoembryonic antigen expression in medullary thyroid carcinoma: possible relation to tumour progression , 2000, Histopathology.

[16]  W. Faquin,et al.  Fine‐needle aspiration biopsy of papillary thyroid carcinoma , 2000, Cancer.

[17]  M. Samii,et al.  Solitary follicular thyroid carcinoma of the skull base and its differentiation from ectopic adenoma — review, use of galectin-3 and report of a new case , 2000, Clinical Neurology and Neurosurgery.

[18]  S. Natsugoe,et al.  Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. , 2000, Human pathology.

[19]  K. Pienta,et al.  Galectin-3 induces endothelial cell morphogenesis and angiogenesis. , 2000, The American journal of pathology.

[20]  M. P. Martegani,et al.  Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  T. Yoshii,et al.  Expression of galectin‐3 in fine‐needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms , 1999, Cancer.

[22]  R. Kiss,et al.  Galectin fingerprinting in tumor diagnosis. Differential expression of galectin-3 and galectin-3 binding sites, but not galectin-1, in benign vs malignant uterine smooth muscle tumors. , 1999, American journal of clinical pathology.

[23]  T. Nishida,et al.  Significance of Biologic Aggressiveness and Proliferating Activity in Papillary Thyroid Carcinoma , 1998, World Journal of Surgery.

[24]  P. De Giuli,et al.  Galectin-3 is a presurgical marker of human thyroid carcinoma. , 1998, Cancer research.

[25]  L. Baum,et al.  Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death , 1998, Journal of Molecular Medicine.

[26]  E. Campo,et al.  GALECTIN‐3 AND LAMININ EXPRESSION IN NEOPLASTIC AND NON‐NEOPLASTIC THYROID TISSUE , 1997, The Journal of pathology.

[27]  J. Figge,et al.  Preferential expression of the cell adhesion molecule CD44 in papillary thyroid carcinoma. , 1994, Experimental and molecular pathology.

[28]  D. Tarin,et al.  Significance of CD44 gene products for cancer diagnosis and disease evaluation , 1992, The Lancet.

[29]  L. Frigeri,et al.  Surface expression of functional IgE binding protein, an endogenous lectin, on mast cells and macrophages. , 1992, Journal of immunology.